超越分期:预测1型糖尿病的个体时间依赖性风险
本研究利用TrialNet的Pathway to Prevention数据开发了三个模型(小型、中型、大型),分别纳入不同风险变量,用于预测1型糖尿病个体化进展风险。所有模型均显著改善了当前分期类别缺失的个体化风险粒度,模型预测风险随年龄增长而降低、随血糖升高和胰岛素分泌降低而升高。在2小时血糖高的人群中,高C肽显著降低预测风险,低C肽则消除了单纯2小时血糖的年龄依赖性风险。
要点
- 所有模型显著改善了当前1型糖尿病分期类别缺失的个体化风险粒度。
- 模型预测风险与年龄增长风险降低、血糖升高和胰岛素分泌降低风险升高一致。
- 在2小时血糖高的人群中,高C肽显著降低预测风险,低C肽消除年龄依赖性风险。
核心结论
- 几乎所有多种自身抗体阳性者都会发展为1型糖尿病,但进展速度异质,不能被任何单一风险变量解释。
- 基于模型的概率提供了可适应的个体化风险计算器,以更好地为临床实践中监测疾病进展的方式和时机提供信息。
研究设计与样本
- 使用TrialNet的Pathway to Prevention数据开发了3个模型:小型模型包括自身抗体状态、空腹血糖、糖化血红蛋白和年龄;中型和大型模型增加了通过口服葡萄糖耐量试验测量的疾病进展预测因素。
主要发现
- 所有模型显著改善了当前1型糖尿病分期类别缺失的个体化风险粒度。
- 模型推导的风险计算与年龄增长风险降低、血糖升高和胰岛素分泌降低风险升高一致。
- 添加血糖和胰岛素分泌数据改变了分期内的模型预测概率。
- 在2小时血糖高的人群中,高C肽显著降低预测风险;较低C肽消除了单纯2小时血糖的年龄依赖性风险,提供了stage 2内疾病进展速度的更细致估计。
临床怎么用
- 作者认为,基于模型的概率提供了可适应的个体化风险计算器,以更好地为临床实践中监测疾病进展的方式和时机提供信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Essentially all individuals with multiple autoantibodies will develop clinical type 1 diabetes. Multiple autoantibodies (AABs) and normal glucose tolerance define stage 1 diabetes; abnormal glucose tolerance defines stage 2. However, the rate of progression within these stages is heterogeneous, necessitating personalized risk calculators to improve clinical implementation. METHODS: We developed 3 models using TrialNet's Pathway to Prevention data to accommodate the reality that not all risk variables are clinically available. The small model included AAB status, fasting glucose, hemoglobin A1c, and age, while the medium and large models added predictors of disease progression measured via oral glucose tolerance testing. FINDINGS: All models markedly improved granularity regarding personalized risk missing from current categories of stages of type 1 diabetes. Model-derived risk calculations are consistent with the expected reduction of risk with increasing age and increase in risk with higher glucose and lower insulin secretion, illustrating the suitability of the models. Adding glucose and insulin secretion data altered model predicted probabilities within stages. In those with high 2-hour glucose, a high C-peptide markedly decreased predicted risk; a lower C-peptide obviated the age-dependent risk of 2-hour glucose alone, providing a more nuanced estimate of the rate of disease progression within stage 2. CONCLUSION: While essentially all those with multiple AABs will develop type 1 diabetes, the rate of progression is heterogeneous and not explained by any individual single risk variable. The model-based probabilities developed here provide an adaptable personalized risk calculator to better inform decisions about how and when to monitor disease progression in clinical practice.
引用
- Pribitzer S, O'Rourke C, Ylescupidez A, et al. Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 38712386. doi:10.1210/clinem/dgae292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。